NA
FATE icon

Neuburgh Advisers’s Fate Therapeutics FATE Stock Holding History

Neuburgh Advisers’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		$30K Hold
1,904
– – ﹤0.01% 863
2019
Q2 		$39K Hold
1,904
– – ﹤0.01% 869
2019
Q1 		$33K Hold
1,904
– – ﹤0.01% 868
2018
Q4 		$24K Buy
+1,904
New +$26.5K ﹤0.01% 856

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
GH
Grosvenor Holdings Chicago, Illinois $512M AUM 19.57% 1-Year Est. Return

Neuburgh Advisers's FATE Position: Q3 2019 in Review

Neuburgh Advisers held its Fate Therapeutics (FATE) position steady in Q3 2019 at 1,904 shares worth $30K. The position accounts for ﹤0.01% of the portfolio, ranked #863.

Neuburgh Advisers first reported a position in FATE in Q4 2018 and has held it in 4 quarters since. The position peaked at $39K in Q2 2019. 149 funds tracked by Wall St. Rank hold FATE as of Q3 2019.

  • Neuburgh Advisers held 1,904 shares of Fate Therapeutics worth $30K as of Q3 2019.
  • Neuburgh Advisers left its Fate Therapeutics share count unchanged in Q3 2019.
  • Fate Therapeutics made up ﹤0.01% of Neuburgh Advisers's portfolio in Q3 2019, its #863 holding.
  • Neuburgh Advisers first reported a position in Fate Therapeutics in Q4 2018 and has held it in 4 quarters since.
  • Neuburgh Advisers's Fate Therapeutics position peaked at $39K in Q2 2019.
  • 149 funds tracked by Wall St. Rank held Fate Therapeutics as of Q3 2019.

Based on Neuburgh Advisers's 13F filing for Q3 2019, filed 14 Nov 2019.